First results for agents targeting cancer-related inflammation.
Garber
Ken
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002465:Cell Movement / Q000276:immunology; D018932:Chemokine CCL2 / Q000276:immunology; D018925:Chemokines / Q000276:immunology; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D054390:Receptors, CCR2 / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018932:Chemokine CCL2; D018925:Chemokines; D016207:Cytokines; D015850:Interleukin-6; D016328:NF-kappa B; D054390:Receptors, CCR2; D019718:Receptors, CXCR4; D014409:Tumor Necrosis Factor-alpha